The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Dr. Leopold Sellner | EBMT 2018 | Idelalisib before allogeneic stem cell transplantation

Mar 23, 2018

44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, PT
Leopold Sellner
University of Heidelberg, Heidelberg, DE

  • Dr Sellner describes a retrospective study by the EBMT Lymphoma Working Party on safety and efficacy of idelalisib use before allogeneic stem cell transplantation (ASCT) in follicular lymphoma.
  • He explains that the results were in line with previous similar studies in lymphoma. Progression-free survival at 12 months was 70%.
  • The main findings of the study showed that idelalisib before ASCT was safe and it was an efficient bridging drug.

Dr. Leopold Sellner | EBMT 2018 | Idelalisib before allogeneic stem cell transplantation